1.00Open0.85Pre Close13 Volume84 Open Interest3.00Strike Price1.39KTurnover166.18%IV1.44%PremiumDec 20, 2024Expiry Date1.17Intrinsic Value100Multiplier7DDays to Expiry0.06Extrinsic Value100Contract SizeAmericanOptions Type0.9394Delta0.1251Gamma3.48Leverage Ratio-0.0082Theta0.0005Rho3.26Eff Leverage0.0007Vega
Trevi Therapeutics Stock Discussion
📊⚡️📊
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Thursday, 12th December at 7:30 am
Independent Data Monitoring Statistician reaffirmed current sample size to remain at N=160
The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the first half of 20...
Trevi Therapeutics Announces Positive Outcome From SAMPLE Size Re-Estimation Resulting in No Change to the Current SAMPLE Size for the Phase 2B Coral Trial in Idiopathic Pulmonary Fibrosis Patients With Chronic Cough
No comment yet